Effect of internal reporting criteria on suspected adverse drug reactions submitted to MedWatch

American Journal of Health-System Pharmacy

Volumn 63, Issue 10, 2006, Pages 949-952

  Smith, Kelly M ^a,b   Lawson, Amber P ^c   Tuteja, Sony ^d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; HEPARIN; MELPHALAN; PHENYTOIN; WARFARIN;

BLEEDING; BLOOD DYSCRASIA; CONGENITAL MALFORMATION; DIARRHEA; DRUG FATALITY; DRUG INFORMATION; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; MENTAL DISEASE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NOTE; ONLINE MONITORING; PHARMACIST; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RESPONSIBILITY; VOMITING;

EID: 33646783603     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050381     Document Type: Note

References (14)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279: 1200-5.
2. Bates DW, Spell N, Cullen DJ et al. The costs of adverse drug events in hospitalized patients. JAMA. 1997; 277:307-11.
3. Classen DC, Pestotnik SL, Evans RS et al. Adverse events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997; 277: 301-6.
4. Suh DC, Woodall BS, Shin SK et al. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother. 2000; 34:1373-9.
5. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002. Arch Intern Med. 2005; 165:1363-9.
6. Food and Drug Administration. MedWatch: the FDA Safety Information and Adverse Event Reporting Program. www.fda.gov/medwatch/report/DESK/advevnt.htm (accessed 2005 Aug 12).
7. American Society of Health-System Pharmacists. ASHP guidelines on adverse drug reaction monitoring and reporting. Am J Health-Syst Pharm. 1995; 52:417-9.
8. Smith KM, Trapskin PJ, Empey PE et al. Internally developed online adverse drug reaction and medication error reporting systems. Hosp Pharm. In press.
9. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.
10. Classen DC, Pestotnik SL, Evans RS et al. Computerized surveillance of adverse drug events in hospital patients. JAMA. 1991; 266:2847-51.
11. Cullen DJ, Bates DW, Leape LL. Prevention of adverse drug events: a decade of progress in patient safety. J Clin Anesth. 2000; 12:600-14.
12. Karch FE, Lasagna L. Adverse drug reactions. A critical review. JAMA. 1975; 234:1236-41.
13. Smith KM, Jeske CS, Young B et al. Prevalence and characteristics of adverse drug reactions in neurosurgical intensive care patients. Neurosurgery. 2006; 58: 426-33.
14. Motl S, Timpe E, Eichner S. Proposal to improve MedWatch: decentralized, regional surveillance of adverse drug reactions. Am J Health-Syst Pharm. 2004; 61:1840-2.